3-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-1-[4-((E)-2-carboxyvinyl)benzyl]-7-methyl-1H-indole

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-1-[4-((E)-2-carboxyvinyl)benzyl]-7-methyl-1H-indole
• 英文别名: 3-(2,3,4,6-Tetra-O-benzyl-beta-D-glucopyranosyl)-1-[4-((E)-2-carboxyvinyl)benzyl]-7-methyl-1H-indole；(E)-3-[4-[[7-methyl-3-[(2S,3S,4R,5R,6R)-3,4,5-tris(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-yl]indol-1-yl]methyl]phenyl]prop-2-enoic acid
• 化学式: C₅₃H₅₁NO₇
• 分子量: 813.99
• InChiKey: BTZOIMKCRLOYQH-YILZLFPCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9
• 重原子数：
  61
• 可旋转键数：
  18
• 环数：
  8.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  88.4
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  3-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-1-(4-iodobenzyl)-7-methyl-1H-indole 、 丙烯酸 在 palladium diacetate 、 三(邻甲基苯基)磷 三乙胺 作用下， 以 乙腈 为溶剂， 生成 3-(2,3,4,6-tetra-O-benzyl-β-D-glucopyranosyl)-1-[4-((E)-2-carboxyvinyl)benzyl]-7-methyl-1H-indole
  参考文献：
  名称：

  1-SUBSTITUTED-3- BETA-D-GLYCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME

  摘要：

  公开号：

  EP1813611B1

文献信息

• [EN] PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY<br/>[FR] DÉRIVÉS DE PIPÉRIDINE EN TANT QUE MODULATEURS D'ACTIVITÉ DE RÉCEPTEUR DE CHIMIOKINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2009015166A1

  公开（公告）日：2009-01-29

  The present application describes modulators of MIP-1 of formula (I) : or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, Q, T, W, Z, R1, R3, R4, R5, R5a and R5b, are as set forth above. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using the modulators are disclosed.

  本申请描述了公式（I）的MIP-1调节剂：或其立体异构体或药用可接受的盐，其中m、Q、T、W、Z、R1、R3、R4、R5、R5a和R5b如上所述。此外，还公开了利用这些调节剂治疗和预防哮喘和过敏性疾病等炎症性疾病，以及类风湿关节炎和动脉粥样硬化等自身免疫病理的方法。
• 1-SUBSTITUTED-3-BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO-CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME
  申请人：Yonekubo Shigeru

  公开号：US20090074738A1

  公开（公告）日：2009-03-19

  A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D-glycopyranosyl) nitrogen-containing heterocyclic compound represented by the general formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate thereof; an SGLT inhibitor containing the same; a pharmaceutical composition containing the same and a combination pharmacy of them. In the formula, A represents an alkylene group or alkenylene group; B represents a single bond, —O—, —S— or —NH—; C represents an optionally substituted aryl or heteroaryl group; Q independently represents a carbon atom which a hydrogen atom or a substituent binds to, or a nitrogen atom.

  一种具有SGLT1和/或SGLT2抑制活性的化合物，可用作预防或治疗糖尿病、餐后高血糖、糖耐量受损、糖尿病并发症、肥胖等的药物。该化合物是一种1-取代-3-(β-D-葡萄糖苷基)氮杂环化合物，其通式表示为(I)，其前药，或其药学上可接受的盐，或其水合物或溶剂化物；包含该化合物的SGLT抑制剂；包含该化合物的制药组合物和药物组合制剂。在该式中，A代表烷基或烯烃基；B代表单键，—O—，—S—或—NH—；C代表可选择取代的芳基或杂芳基；Q独立地表示氢原子或取代基结合的碳原子或氮原子。
• 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：US07750145B2

  公开（公告）日：2010-07-06

  A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D-glycopyranosyl) nitrogen-containing heterocyclic compound represented by the general formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate thereof; an SGLT inhibitor containing the same; a pharmaceutical composition containing the same and a combination pharmacy of them. In the formula, A represents an alkylene group or alkenylene group; B represents a single bond, —O—, —S— or —NH—; C represents an optionally substituted aryl or heteroaryl group; Q independently represents a carbon atom which a hydrogen atom or a substituent binds to, or a nitrogen atom.

  具有SGLT1和/或SGLT2抑制活性的化合物，可用作预防或治疗糖尿病、餐后高血糖、糖耐量受损、糖尿病并发症、肥胖等药物。它是一种1-取代-3-（β-D-葡萄糖苷基）含氮杂环化合物，代表通式（I），其前药，或其药学上可接受的盐，或其水合物或溶剂化物；含有SGLT抑制剂的化合物；含有该化合物的制药组合物。在该式中，A代表烷基或烯基；B代表单键，-O-，-S-或-NH-；C代表可选取代的芳基或杂环芳基；Q独立地表示氢原子或取代基连接的碳原子或氮原子。
• 1-SUBSTITUTED-3- BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1813611A1

  公开（公告）日：2007-08-01

  A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D-glycopyranosyl) nitrogen-containing heterocyclic compound represented by the general formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate thereof; an SGLT inhibitor containing the same; a pharmaceutical composition containing the same and a combination pharmacy of them. In the formula, A represents an alkylene group or alkenylene group; B represents a single bond, -O-, -S- or -NH-; C represents an optionally substituted aryl or heteroaryl group; Q independently represents a carbon atom which a hydrogen atom or a substituent binds to, or a nitrogen atom.

  一种具有 SGLT1 和/或 SGLT2 抑制活性的化合物，可用作预防或治疗糖尿病、餐后高血糖、糖耐量受损、糖尿病并发症、肥胖症等的药物。它是由通式（I）代表的1-取代-3-（β-D-吡喃糖基）含氮杂环化合物、其原药或其药学上可接受的盐，或其水合物或溶液；含有相同物质的SGLT抑制剂；含有相同物质的药物组合物以及它们的组合药剂。式中，A代表烯基或烯基；B代表单键、-O-、-S-或-NH-；C代表任选取代的芳基或杂芳基；Q独立地代表氢原子或取代基结合的碳原子或氮原子。
• PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  申请人：Bristol-Myers Squibb Company

  公开号：EP2173714A1

  公开（公告）日：2010-04-14